SCHEDULE: Morgan Stanley Reports 8% Stake in BioVie Inc.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed beneficial ownership of 8.0% of BioVie Inc.'s Class A Common Stock as of June 30, 2026.

Summary

• Morgan Stanley and Morgan Stanley Smith Barney LLC jointly filed a Schedule 13G, indicating their beneficial ownership of BioVie Inc.'s Class A Common Stock.
• As of June 30, 2026, the total beneficial ownership reported is 605,472 shares, representing 8.0% of the class of securities.
• Morgan Stanley Smith Barney LLC is identified as the entity holding the shares, with Morgan Stanley acting as the parent holding company.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting ownership stakes rather than new strategic or financial performance information.

Positives

• Disclosure of a significant institutional investor's stake can sometimes signal confidence in the company's long-term prospects.
• The filing confirms adherence to regulatory reporting requirements by Morgan Stanley.

Negatives

• The filing does not provide any new financial performance data or strategic updates for BioVie Inc.
• The information is purely a reporting of an existing ownership position, offering no new insights into BioVie's operations or future.

Risks

• Potential for future changes in Morgan Stanley's ownership stake, which could impact BioVie's stock price.
• The filing does not offer any forward-looking statements or risk disclosures specific to BioVie Inc.'s business operations.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding BioVie Inc.'s future performance.

Management Comments

• Morgan Stanley and Morgan Stanley Smith Barney LLC certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors crossing certain ownership thresholds. This filing indicates Morgan Stanley's established position as a significant shareholder in BioVie Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holder, which may influence market perception, but does not directly alter existing share value or rights.
• Management: The filing reinforces that the reporting entity does not intend to influence control, aligning with standard corporate governance practices.

Next Steps

• Morgan Stanley and Morgan Stanley Smith Barney LLC will continue to report any changes in their beneficial ownership of BioVie Inc. Class A Common Stock as required by SEC regulations.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Morgan Stanley, BioVie Inc., Class A Common Stock, Institutional Investor, SEC Filing